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Introduction: Percent mammographic density (PMD) is associated with an increased risk of interval breast cancer
in screening programs, as are younger age, pre-menopausal status, lower body mass index and hormone therapy.
These factors are also associated with variations in PMD. We have examined whether these variables influence
the relative frequency of interval and screen-detected breast cancer, independently or through their associations
with PMD. We also examined the association of tumor size with PMD and dense and non-dense areas in screen-detected
and interval breast cancers.
Methods: We used data from three case-control studies nested in screened populations. Interval breast cancer was
defined as invasive breast cancer detected within 12 months of a negative mammogram. We used a computer-assisted
method of measuring the dense and total areas of breast tissue in the first (baseline) mammogram taken at entry to
screening programs and calculated the non-dense area and PMD. We compared these mammographic features, and
other risk factors at baseline, in women with screen-detected (n = 718) and interval breast cancer (n= 125).
Results: In multi-variable analysis, the baseline characteristics of younger age, greater dense area and smaller non-dense
mammographic area were significantly associated with interval breast cancer compared to screen-detected breast cancer.
Compared to screen-detected breast cancers, interval cancers had a larger maximum tumor diameter within
each mammographic measure.
Conclusions: Age and the dense and non-dense areas in the baseline mammogram were independently associated
with interval breast cancers in screening programs. These results suggest that decreased detection of cancers caused by
the area of dense tissue, and more rapid growth associated with a smaller non-dense area, may both contribute to risk of
interval breast cancer. Tailoring screening to individual mammographic characteristics at baseline may reduce the number
of interval cancers.Introduction
Screening for breast cancer with mammography is moti-
vated by the evidence that the pre-symptomatic detec-
tion and treatment of the disease reduces mortality from
breast cancer [1,2]. Reduction of mortality from breast
cancer by mammographic screening is possible because
a substantial number of breast cancers have a prolonged
period of time (the sojourn time) before they give rise to
symptoms or signs, during which they can be detected* Correspondence: boyd@uhnres.utoronto.ca
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unless otherwise stated.by mammography and cured with currently available
treatments [3].
Not all breast cancers, however, are detected by mam-
mography and some are detected clinically in the interval
after a negative screening mammogram. Such ‘interval’
breast cancers have been associated with several factors
including younger age, pre-menopausal status, lower body
mass index (BMI), and greater mammographic density and
hormone therapy [4-7].
In a published case-control study nested within three
cohorts of women undergoing mammographic screening
we found that, compared to women with less than 10%
density in the mammogram, women with more than
75% density had a increased risk of breast cancer (odds
ratio: 4.7; 95% confidence interval: 3.0, 7.4). For womend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ratio for >75% density compared to <10% was 3.5 (95%
CI: 2.0, 6.2). For women in whom breast cancer was de-
tected 12 months or less after a negative screening
mammogram the odds ratio for >75% density compared
to <10% was 17.8 (95% CI: 4.8, 65.9). For women in
whom breast cancer was detected more than 12 months
after a negative screening mammogram the odds ratio
for >75% density compared to <10% was 5.7 (95% CI:
2.1, 15.5) [8].
Age, menopausal status, BMI, and hormone therapy
are all associated with variations in mammographic
density that may ‘mask’ breast cancer and make detec-
tion more difficult [9-11]. It is not known whether these
factors influence risk of interval cancers independently,
or through their associations with density. The purpose
of the present manuscript was to examine the associ-
ation of interval breast cancer in screening programs
with these other factors and with the measured compo-
nents of percent density, the dense and non-dense areas
in the baseline mammogram. We also examined the
association of tumor size with these mammographic
features in screen-detected and interval breast cancers.
Because the large increase in risk of breast cancer as-
sociated with mammographic density after a negative
screening mammogram was limited to the 12 months
following screening we have confined the present ana-
lysis to a comparison of two groups, women with breast
cancer detected at screening and women with breast




We have carried out a study using data from three nested
case-control studies carried out in populations screened
with mammography. We measured mammographic
density in the first (baseline) mammogram obtained
at entry to each screening program with a computer-
assisted quantitative method [12], and compared theTable 1 Selected characteristics of mammographic screening
Program National Breast S
Years of operation 1984-90
Incident cancers selected for present study in years 1984-90
Number of first examinations in selected years 45,000
Recruitment Self-referral
Number of centers 15
Ages 40-59
Frequency of screening Annual
Physical examination Yesbaseline mammographic, demographic and other charac-
teristics of women who developed breast cancer detected
by screening with those who developed interval breast
cancers. Ethical approval of the study was obtained from
the University of Toronto, The University Health Network
(Toronto), The Ontario Breast Screening Program, and the
University of British Columbia.
Screened populations
Selected characteristics of the screened populations in-
cluded in this study are shown in Table 1. The National
Breast Screening Study (NBSS) was a randomized trial
of screening with mammography and physical examin-
ation [13]. The Screening Mammography Program of
British Columbia (SMPBC) uses mammography as the
only screening modality at the screening center, and
the Ontario Breast Screening Program (OBSP) uses
mammography and physical examination as screening
modalities.
Selection of subjects
For the OBSP and SMPBC, lists were prepared of sub-
jects with histologically verified invasive breast cancer
diagnosed during the years 1992 to 1998 for the OBSP,
and 1993 to 1999 for the SMPBC. Subjects diagnosed
with breast cancer within 12 months of their first screening
examination were excluded. For each case, the method of
breast cancer detection, whether or not at screening, was
determined by each program, independently of this study,
and was based upon the active follow-up of women in
whom abnormalities had been found. In addition, each pro-
gram periodically carried out linkages with provincial and
national cancer registries to identify breast cancers diag-
nosed in screened subjects in whom breast cancer had not
been detected at screening.
Informed consent had been obtained at entry to the
NBSS for research applications using the data collected,
and all 354 subjects diagnosed with invasive breast
cancer between 1984 and 1990, were included [14]. Eli-
gible cases in the OBSP and SMPBC were sent a letter,programs










Annual Every 2 years
No Yes
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formed consent for the release of their mammogram,
and to complete a self-administered questionnaire (see
below). Fifty percent of cases selected from the OBSP
and SMPBC agreed to take part.
Data collection
In the NBSS, information on risk factors for breast
cancer was obtained at the time of entry by self-
administered questionnaire. For the other two pro-
grams, information was collected by self-administered
questionnaire at the time of recruitment into the
present study. Questions included demographic infor-
mation, use of hormone therapy, including the date
started and duration of use, as well as menstrual and
reproductive risk factors, and self-reported height and
weight, from which BMI was calculated. All informa-
tion was collected with reference to the time of the
first (baseline) screening mammogram.
Selection and/or recall bias might influence information
about risk factors obtained in the OBSP and SMPBC,
but not the NBSS. However, the distribution of non-
mammographic risk factors was similar in all three
programs and we also observed the expected effects of
most known risk factors in all programs [8]. Age-
adjusted BMI at entry to each screening program was
correlated with percent mammographic density in the
first screening mammogram in the NBSS (r = −0.39),
OBSP (r = −0.43) and the SMPBC (r = −0.45). In light
of the similarity of results in all three programs, selec-
tion or recall bias in the OBSP and SMPBC is unlikely.
The maximum diameter of breast cancers was deter-
mined by macroscopic examination and was extracted
from pathology reports obtained from the screening
programs.
Mammographic density assessment
Mammographic density was measured using a previously
described computer-assisted method [12]. One cranio-
caudal image was digitized for each subject, using a
Lumisys 85 digitizer, and measured by one observer
(NFB), in sets of approximately 120, with equal numbers
of randomly ordered cases and controls. A 10% random
sample of images was re-read, within and between each
session, and reliability was 0.94 both within and between
reads.
Statistical methods
Of the 1,209 cases recruited, 95 were excluded because
of missing data (NBSS = 24; OBSP = 34; SMPBC = 37),
leaving a total of 1,114 cases. Of these, 718 had been de-
tected by screening, 125 were detected in the 12 months
after a negative screening mammogram, and 271 more
than 12 months after a negative screen. In the analysis,we compared the characteristics of women with breast
cancer detected by screening with those with breast
cancer found in the 12-month interval after a negative
screen.
We used univariable logistic regression analysis to
examine the associations of demographic and anthropo-
metric variables, and mammographic measures of per-
cent density, dense area and non-dense area with the
relative frequency of interval breast cancer compared to
screen-detected breast cancer. We then carried out mul-
tivariable analyses to compare features associated with
the relative frequency of interval and screen-detected
breast cancers, adjusting the demographic and anthropo-
metric variables for each of the three mammographic
measurements, as well as for the dense and non-dense
areas together. To illustrate the magnitude and directions
of the associations found, we divided percent density, dense
area and non-dense area into tertiles. Although in other
studies we found it necessary to apply a transformation to
the three mammographic measures, in this study we
present results based on the tertiles of these variables,
which will not be affected by a monotonic transformation.
We use, as is common in medical research, an independ-
ent risk factor to denote a variable that has a significant
contribution to an outcome in a statistical model that
includes other established risk factors [15].
To examine the association between maximum tumor
diameter and tertiles of percent density, dense area and
non-dense area, we used multiple linear regression
models adjusted for age, BMI and menopausal status
that included an interaction with the cancer detection
method. We compared the least square means of max-
imum tumor diameter obtained from these models in
screen-detected and interval breast cancers within tertiles
of mammographic measures, and we tested for linear
trends across tertiles of mammographic measures. Tumor
diameter was log transformed to improve the symmetry of
the distribution and stabilize the variance, and the results
are shown after back-transformation.
Results
Characteristics of subjects with screen-detected and interval
breast cancers
Table 2 shows selected characteristics of women with
breast cancer detected at screening and those in whom
breast cancer was detected within 12 months of negative
screening mammogram. The statistical comparisons shown
were performed without adjustment for the other factors
shown in the Table. In univariable analysis, younger age,
lower BMI, and pre-menopausal status, a greater percent
density, a greater area of dense tissue, and a smaller area of
non-dense tissue, were all significantly and positively associ-
ated with breast cancer detected within 12 months of a
negative screening examination. The total breast area was
Table 2 Selected characteristics of screen-detected and
interval cancers







Age (years) 57.2 (9.0) 52.8 (8.3) <0.0001
Body mass index (kg/m2) 25.3 (4.3) 23.9 (3.5) 0.0008





Parity (% parous) 84.3 82.4 0.60














Current use of HRTb (% yes) 18.3 20.8 0.50




breast cancer (% yes)
20.6 N = 714 20.0 0.88
Percent mammographic
density
30.3 (19.1) 42.2 (20.4) <0.0001
Dense area (cm2) 36.7 (25.6) 45.3 (28.5) 0.001
Non-dense area (cm2) 100.4 (60.1) 67.2 (44.6) <0.0001
Total area (cm2) 137.0 (60.4) 112.5 (54.2) <0.0001
aP value is from the univariable logistic regression model analysis of risk of
interval vs. screen-detected breast cancer; bhormone replacement therapy.
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ation was entirely accounted for by the dense and non-
dense areas. The other variables shown in the table were
not significantly associated with interval breast cancer.
Comparison of subjects with screen-detected and interval
breast cancers: multivariable analysis
Figure 1 shows the associations of tertiles of age and
BMI with the frequencies of screen-detected and interval
breast cancers. Odds ratios for the relative frequency of
interval breast cancers were calculated with reference to
the lowest tertile of age and BMI and are shown before
and after mutual adjustment. Menopausal status was no
longer significantly associated with interval breast cancer
after adjustment for age and is omitted from further
analyses (data not shown).
In the lowest tertile of age (mean = 47 years) 59 of a total
of 273 cancers (22%) were detected in the 12 months after
a negative screen while in the highest tertile of age (mean =
67 years) 21 of a total of 281 cancers (7%) were interval
cancers. Compared to the lowest tertile of age the highest
tertile of age was associated with an odds ratio of 0.29 (95%
CI: 0.17, 0.48) after adjustment for BMI indicating asignificant reduction in the relative frequency of interval
breast cancers with increasing age. After additional adjust-
ment for the dense and non-dense areas of the mammo-
gram, age remained significantly associated with a reduced
relative frequency of interval breast cancer.
In the lowest tertile of BMI (mean = 21) 51 of a total
of 281 cancers (18%) were detected in the 12 months
after a negative screen while in the highest tertile of BMI
(mean = 30) 27 of a total of 281 cancers (10%) were
interval cancers. Compared to the lowest tertile of BMI,
the highest tertile of BMI was associated with an odds
ratio of 0.50 (95% CI: 0.30, 0.82) after adjustment for
age, indicating a significant reduction in the relative fre-
quency of interval breast cancer with increasing BMI.
Additional adjustment for dense area alone produced
similar odds ratios (data not shown), however, after
additional adjustment for both the dense and non-dense
areas of the mammogram, BMI was no longer significantly
associated with a reduced relative frequency of interval
breast cancer (OR: 0.75; 95% CI: 0.42, 1.34).
Figure 2 shows the associations of percent density, dense
and non-dense areas with screen-detected and interval
breast cancer according to the tertiles of each variable.
Odds ratios for the relative frequency of interval breast can-
cers were calculated with reference to the lowest tertile of
each mammographic measure and are shown before and
after adjustment for age and BMI, and additional mutual
adjustment of the dense and non-dense areas.
In the lowest tertile of percent mammographic density
(PMD) (mean = 11%) 18 of a total of 282 cancers (6%)
were detected in the 12 months after a negative screen
while in the highest tertile of PMD (mean = 55%) 63 of a
total of 282 cancers (22%) were interval cancers. Com-
pared to the lowest tertile of PMD, the highest tertile of
PMD was associated with an odds ratio of 2.63 (95% CI:
1.46, 4.94) after adjustment for age and BMI.
In the lowest tertile of dense area (mean = 14 cm2), 29
of a total of 281 cancers (10%) were detected in the 12
months after a negative screen while in the highest ter-
tile of dense area (mean = 67 cm2) 57 of a total of 281
cancers (20%) were interval cancers. Compared to the
lowest tertile of dense area, the highest tertile of dense
area was associated with an odds ratio of 1.79 (95% CI:
1.79, 2.97) after adjustment for age and BMI indicating a
significantly greater relative frequency of interval breast
cancers with increasing dense area. After adjustment for
age and BMI, and the non-dense area, the association of
the dense area with interval cancers remained positive
(OR = 1.59; 95% CI: 0.96, 2.66), but was no longer statis-
tically significant.
In the lowest tertile of non-dense area (mean = 40
cm2) 60 of a total of 281 cancers (21%) were detected in
the 12 months after a negative screen while in the high-
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= 0.50 [0.30; 0.82]
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Referent category Referent category
Figure 1 Screen-detected and interval breast cancers according to tertiles of age and BMI at entry. Tertiles of age: Low (39 to 52); Middle
(52 to 60); High (60 to 80). Tertiles of BMI: Low (16 to 23); Middle (23 to 26); High (26 to 50). aUnadjusted; bmutually adjusted (age and BMI);
cmutually adjusted and adjusted for dense and non-dense area. BMI: body mass index; OR: odds ratio.
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lowest tertile of non-dense area, the highest tertile of
non-dense area was associated with an odds ratio of 0.40
(95% CI: 0.20, 0.77) after adjustment for age and BMI,
indicating a significant reduction in the relative frequency
of interval breast cancers with increasing non-dense area.
The non-dense area remained inversely and significantly
associated with the relative frequency of interval and
screen-detected breast cancers (OR = 0.43; 95% CI: 0.21,
0.85) after additional adjustment for the dense area.
Results were unchanged when continuous measures of
mammographic features were used (data not shown).
Tumor size and mammographic measures
Table 3 shows the least square means of maximum
tumor diameter for screen-detected and interval breast
cancers adjusted for the other factors shown in the table
footnote. Average maximum tumor diameter was greaterin interval cancers than in screen-detected cancers
within each tertile of each mammographic measure and,
as shown in Table 3, these differences were statistically
significant in most of the comparisons shown. Tests for
trend in the differences in the least square means of
average tumor diameter were not statistically significant
over tertiles of any mammographic measures.
In all cancers, after adjustment for age, BMI and meno-
pausal status, the dense area was significantly and positively
associated with maximum tumor diameter when both were
treated as continuous variables (P = 0.04).
Discussion
An improved understanding of the factors that influence
the frequency of interval breast cancers in screening pro-
grams may be useful in the selection of the methods and
the frequency with which women are screened. Breast can-



















































































































= 2.73 [1.56; 4.97]
OR
b
= 2.15 [1.21; 3.97]
OR
a
= 4.24 [2.49; 7.57]
OR
b
= 2.63 [1.46; 4.94]
OR
a
= 1.40 [0.84; 2.35] 
OR
b
= 1.22 [0.72; 2.06]
OR
c
= 1.09 [0.64; 1.86]
OR
a
= 2.21 [1.38; 3.62]
OR
b
= 1.79 [1.10; 2.97]
OR
c
= 1.59 [0.96; 2.66]
OR
a
= 0.76 [0.50; 1.16]
OR
b
= 0.99 [0.62; 1.56]
OR
c
= 1.02 [0.64; 1.62]
OR
a
= 0.24 [0.13; 0.41]
OR
b
= 0.40 [0.20; 0.77]
OR
c
= 0.43 [0.21; 0.85]
Referent category Referent category Referent category
Figure 2 Screen-detected and interval breast cancers according to tertiles of percent density, dense and non-dense area. Tertiles of
percent density: Low (0 to 20); Middle (20 to 41); High (41 to 84). Tertiles of dense area: Low (0 to 24); Middle (24 to 43); High (43 to 176). Tertiles
of non-dense area: Low (8 to 61); Middle (61 to 112); High (112 to 344). aUnadjusted; badjusted for age and BMI; cmutually adjusted (dense and
non-dense area) and adjusted for age and BMI. OR: odds ratio.
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occur for several reasons. Tumors might have been present
but not detected on the previous screening examination
and failure of detection might be due to radiological or
technical error, or because the signs of the tumor were
‘masked’ by dense breast tissue. Alternatively, some cancers
might have been present but too small to be detected by
mammography, and grow to become clinically detectable
in the interval before the next screen. Cancers that behave
in this way are likely to have a greater than average rate of
growth and a shorter than average sojourn time.
The factors previously described as associated with
‘interval’ cancers in screening programs include younger
age, lower weight or BMI, pre-menopause status and use
of hormone therapy, and mammographic density. Youn-
ger age, lower weight, pre-menopausal status [9,10,16]and use of combined hormone therapy [11,17-19] are all
known to be associated with a greater area of mammo-
graphically dense breast tissue. With the exception of
hormone therapy, these factors are all shown here in
Canadian screening programs to be associated with a
greater relative frequency of interval breast cancer com-
pared to screen-detected breast cancer. We have shown
in a separate study that the effect of hormone therapy
use on risk of interval cancers is also independent of
mammographic density [20].
As we show here, PMD and its constituent elements,
the dense and non-dense areas of the mammogram,
were each associated with risk of interval breast cancer.
The relative frequency of interval breast cancer in-
creased with greater percent density and area of dense
tissue and decreased with a greater area of non-dense






Least squares means (cms)a (95% CI) by tertiles of mammographic measures
Low Middle High P valueb
Percent density All 1.29 (1.16, 1.42) N = 277 1.46 (1.32, 1.60) N = 269 1.45 (1.32, 1.60) N = 275 0.34
Screen detected 1.25 (1.13, 1.39) N = 260 1.36 (1.23, 1.51) N = 228 1.36 (1.22, 1.51) N = 213 0.16
Interval cancers 1.50 (1.06, 2.13) N = 17 2.02 (1.61, 2.54) N = 41 1.87 (1.55, 2.26) N = 62 0.09
P valuec 0.324 0.002 0.003
Dense area All 1.33 (1.20, 1.47) N = 275 1.35 (1.22, 1.48) N = 273 1.50 (1.37, 1.65) N = 273 0.12
Screen detected 1.27 (1.15, 1.41) N = 247 1.27 (1.15, 1.40) N = 236 1.43 (1.29 1.50) N = 218 0.43
Interval cancers 1.66 (1.26, 2.19) N = 28 1.98 (1.56, 2.52) N = 37 1.87 (1.53, 2.27) N = 55 0.06
P valuec 0.068 0.001 0.017
Non-dense area All 1.39 (1.25, 1.54) N = 276 1.45 (1.31, 1.60) N = 271 1.35 (1.22, 1.51) N = 274 0.93
Screen detected 1.31 (1.17, 1.46) N = 216 1.39 (1.25, 1.55) N = 227 1.29 (1.16, 1.44) N = 258 0.78
Interval cancers 1.84 (1.51, 2.24) N = 60 1.81 (1.45, 2.25) N = 44 2.06 (1.43, 2.96) N = 16 0.78
P valuec 0.002 0.031 0.013
aLeast squares means were obtained from linear regression models with an interaction between cancer detection method and tertiles of mammographic
measures. Tumor diameter in cms was log transformed for the analysis. Least squares means and their 95% confidence intervals (CIs) are shown transformed back
to the original scale. For N = 15 subjects with recorded tumor size = 0, the minimum recorded tumor size = 0.1 cm was used in the analysis. For N = 17 subjects
with screen detected, and for N = 5 subjects with interval breast cancer the tumor diameter was not available. For tertiles of percent mammographic density, the
model was adjusted for age, body mass index, and menopausal status. For tertiles of dense area, the model was, in addition, adjusted for non-dense area (continuous), and
for tertiles of non-dense area, the model was adjusted for dense area (continuous). bP values for the test for linear trend across tertiles of mammographic measurements.
cP values for comparing least square means of maximum tumor diameter in screen-detected and interval breast cancers within tertiles of mammographic
measures. The P values were adjusted for multiple comparisons (the Tukey-Kramer adjustment).
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rendered non-significant the previously significant asso-
ciation of BMI with interval breast cancer. Younger age
however remained significantly and independently asso-
ciated with an increased relative frequency of interval
cancer after all adjustments. After adjustment, greater
percent density and smaller non-dense areas of the
mammogram also remained significantly associated with
the frequency of interval cancers.
Although younger age is known to be associated with
greater PMD [9,10], the associations of age with the fre-
quency of interval breast cancer was independent of the
mammographic measures analyzed. Age may thus influ-
ence the frequency of interval cancers in part by an in-
fluence on the biological behavior of tumors, rather than
by masking due to greater density. Interval cancers have
been shown to have biological characteristics including a
higher proportion of proliferating cells and more fre-
quent expression of p53 [21] that suggest more rapid
tumor growth. Also consistent with more rapid growth
was the finding that interval cancers had a larger max-
imum tumor diameter within each tertile of the mam-
mographic measures examined. However, in contrast to
some previous studies, we did not find an association
between tumor size and percent density in screen-
detected or interval breast cancers [22]. Greater hormo-
nal stimulation of breast cell proliferation and tumor
growth are potential mechanisms by which younger age
might influence the frequency of interval breast cancers.The additional and independent effect of a greater
BMI-adjusted non-dense area in reducing the relative
frequency of interval breast cancer may also be the re-
sult of biological factors that influence tumor growth.
The non-dense tissue in the adult breast is composed of
adipose tissue and the lipid-laden adipocytes that form
this tissue arise from the differentiation of stromal mes-
enchymal cells. Aromatase activity in the breast provides
a source of estrogen production that may stimulate
tumor growth. As reviewed in Simpson et al. [23] adi-
pose tissue aromatase is expressed primarily in stromal
mesenchymal cells, rather than in lipid-laden adipocytes,
and aromatase in adipose tissue is thus a marker of the
undifferentiated adipose mesenchymal cell. Aromatase
activity in stromal mesenchymal cells diminishes with
differentiation to mature adipocytes [23,24]. The reduction
of this source of estrogen after adipocyte differentiation
might contribute to the inverse association observed be-
tween the area of non-dense tissue on mammography and
the frequency of interval breast cancer.
Strengths of the present study include the relatively
large number of breast cancers from three screening
programs in Canada. Each program had classified tu-
mors as having been detected by screening or by other
means, and the method of detection played no role in
the sampling of subjects for the present study and was
unknown at the time mammographic measurements
were made. We used a computer-assisted method of
measuring mammographic features that has been shown
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associated with breast cancer risk. Further, we had a
complete set of potentially relevant covariates that were
included in the analysis.
Limitations of the study include our exclusive reliance on
film rather than digital images. However, a population-
based study carried out in the Norwegian Breast Cancer
Screening Program by Hofvind et al. compared the per-
formance of screen-film mammography (SFM) and full-
field digital mammography (FFDM) in women aged 50 to
69 years. The rates of invasive interval breast cancer were
2220/1,391,188 (0.17/1000) with SFM and 309/446,172
(0.12/1000) with FFDM, a difference that was not statisti-
cally significant (P = 0.07) [17].
The location of tumors in the breast and other aspects
of the phenotype of the breast cancers were also not
available to us. Domingo et al. have shown that aspects
of the tumor phenotype, including HER2-positive and
triple-negative tumors, and breast density are independ-
ently associated with interval breast cancers [25].
The results of the present study suggest that mammo-
graphic screening with a single imaging modality and a
fixed screening interval for all women may not be opti-
mal. Several independent sources of variation in the de-
tection of breast cancer by screening are identified that
are personal characteristics of individual women present
at the time screening was initiated. The incorporation of
these factors into the design and execution of screening
programs for breast cancer might improve the outcomes of
screening, extend the ages at which screening is carried
out, and further reduce mortality from breast cancer.
In addition to digital mammography, that has now
largely replaced film [26], alternative modalities include
ultrasound [27], and magnetic resonance imaging [28].
Although it is known that each of these modalities can
detect some breast cancers that are not seen on film
mammography, their value as alternatives to mammog-
raphy in the context of screening is largely unknown.
Modulation of the screening interval according to charac-
teristics that influence risk of interval cancers might also be
considered, with shorter intervals for younger women with
extensive dense breast tissue and longer intervals for older
women with radiolucent breasts on mammography.
Conclusions
Compared to women with screen-detected breast cancer,
younger age and a greater dense area and smaller non-
dense areas in the baseline mammogram were independ-
ently associated with a greater frequency of interval breast
cancers in screening programs. These results suggest that
decreased detection of cancers caused by the area of dense
tissue, and more rapid growth associated with a smaller
non-dense area, may both contribute to the frequency of
interval breast cancers.Abbreviations
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